1
|
Chu Y, Raja Sekhara Reddy B, Pratap Reddy Gajulapalli V, Sudhakar Babu K, Kim E, Lee S. Design, synthesis, and biological evaluation of N-arylpiperazine derivatives as interferon inducers. Bioorg Med Chem Lett 2020; 30:127613. [PMID: 33075488 PMCID: PMC7566768 DOI: 10.1016/j.bmcl.2020.127613] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2020] [Revised: 10/09/2020] [Accepted: 10/12/2020] [Indexed: 01/19/2023]
Abstract
We designed and synthesized a series of arylpiperazine derivatives as interferon inducers. We tested different linker system and carbonyl moiety resulted in increase of potency. 5i exhibited the activity of interferon inducer with EC50 of 13.1 μM and no cytotoxicity. 5i initiated immune responses by mediating type I IFN signaling.
Type I Interferon (IFN) signaling plays an important role in the immune defense system against virus infection and in the innate immune response, thus IFNs are widely used as anti-viral agents and treatment for immune disorder or cancer. However, there is a growing demand for novel small-molecule IFN inducer due to tolerance, toxicity, or short duration of action following direct administration of IFNs. In this study, we assessed arylpiperazine (ARP) as a new core skeleton of IFN inducer. To investigate structure–activity relationship, we designed and synthesized a series of ARP analogues and evaluated the ability to stimulate IFN response in THP-1 human monocyte cells. Compound 5i was identified as a potent type I IFN inducer as it significantly increased cytokine secretion and increased expression of various IFN-stimulating genes which are representative biomarkers of type I IFN pathway. Our results suggested a beneficial therapeutic potential of 5i as an anti-viral agent.
Collapse
Affiliation(s)
- Yeonjeong Chu
- Brain Science Institute, Korea Institute of Science and Technology, Seoul, South Korea; Department of Molecular Science and Technology, Ajou University, Suwon, South Korea
| | | | | | - K Sudhakar Babu
- Department of Chemistry, Sri Krishnadevaraya University, Anantapur, India.
| | - Eunha Kim
- Department of Molecular Science and Technology, Ajou University, Suwon, South Korea.
| | - Sanghee Lee
- Brain Science Institute, Korea Institute of Science and Technology, Seoul, South Korea; Department of HY-KIST Bio-convergence, Hanyang University, Seoul, South Korea.
| |
Collapse
|
2
|
Arias MH, Quiliano M, Bourgeade-Delmas S, Fabing I, Chantal I, Berthier D, Minet C, Eparvier V, Sorres J, Stien D, Galiano S, Aldana I, Valentin A, Garavito G, Deharo E. Alsinol, an arylamino alcohol derivative active against Plasmodium, Babesia, Trypanosoma, and Leishmania: past and new outcomes. Parasitol Res 2020; 119:3503-3515. [PMID: 32772176 DOI: 10.1007/s00436-020-06832-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2019] [Accepted: 07/26/2020] [Indexed: 12/14/2022]
Abstract
Malaria, babesiosis, trypanosomosis, and leishmaniasis are some of the most life-threatening parasites, but the range of drugs to treat them is limited. An effective, safe, and low-cost drug with a large activity spectrum is urgently needed. For this purpose, an aryl amino alcohol derivative called Alsinol was resynthesized, screened in silico, and tested against Plasmodium, Babesia, Trypanosoma, and Leishmania. In silico Alsinol follows the Lipinski and Ghose rules. In vitro it had schizontocidal activity against Plasmodium falciparum and was able to inhibit gametocytogenesis; it was particularly active against late gametocytes. In malaria-infected mice, it showed a dose-dependent activity similar to chloroquine. It demonstrated a similar level of activity to reference compounds against Babesia divergens, and against promastigotes, and amastigotes stages of Leishmania in vitro. It inhibited the in vitro growth of two African animal strains of Trypanosoma but was ineffective in vivo in our experimental conditions. It showed moderate toxicity in J774A1 and Vero cell models. The study demonstrated that Alsinol has a large spectrum of activity and is potentially affordable to produce. Nevertheless, challenges remain in the process of scaling up synthesis, creating a suitable clinical formulation, and determining the safety margin in preclinical models.
Collapse
Affiliation(s)
- Maria H Arias
- Facultad de Ciencias, Departamento de Farmacia, Grupo de Investigación FaMeTra (Farmacología de la Medicina Tradicional y Popular), Universidad Nacional de Colombia, Sede Bogotá, Carrera 30 45-03, Bogotá D.C., 111321, Colombia
| | - Miguel Quiliano
- Faculty of Health Sciences, Centre for Research and Innovation, Universidad Peruana de Ciencias Aplicadas (UPC), 15023, Lima, Peru
| | - Sandra Bourgeade-Delmas
- UMR 152 PHARMA-DEV, Institut de Recherche pour le Développement IRD, Université de Toulouse UPS, Toulouse, France
| | - Isabelle Fabing
- Laboratoire de Synthèse et Physicochimie de Molécules d'Intérêt Biologique (SPCMIB), Centre National de la Recherche Scientifique (CNRS), 31062, Cedex 09, Toulouse, France
| | - Isabelle Chantal
- UMR INTERTRYP, CIRAD, F-34398, Montpellier, France.,INTERTRYP, Univ Montpellier, CIRAD, IRD, Montpellier, France
| | - David Berthier
- UMR INTERTRYP, CIRAD, F-34398, Montpellier, France.,INTERTRYP, Univ Montpellier, CIRAD, IRD, Montpellier, France
| | - Cécile Minet
- UMR INTERTRYP, CIRAD, F-34398, Montpellier, France.,INTERTRYP, Univ Montpellier, CIRAD, IRD, Montpellier, France
| | - Veronique Eparvier
- ICSN-CNRS UPR 2301 Équipe "Métabolites de végétaux et micro-organismes associés: isolement, synthèse et bioactivité", 91198 cedex, Gif-sur-Yvette, France
| | - Jonathan Sorres
- ICSN-CNRS UPR 2301 Équipe "Métabolites de végétaux et micro-organismes associés: isolement, synthèse et bioactivité", 91198 cedex, Gif-sur-Yvette, France
| | - Didier Stien
- Laboratoire de Biodiversité et Biotechnologie Microbienne, LBBM, Observatoire Océanologique, CNRS, Sorbonne Université, 66650, Banyuls-sur-mer, France
| | - Silvia Galiano
- Facultad de Farmacia y Nutrición, Departamento de Química Orgánica y Farmacéutica, Universidad de Navarra, Campus Universitario, 31008, Pamplona, Spain
| | - Ignacio Aldana
- Facultad de Farmacia y Nutrición, Departamento de Química Orgánica y Farmacéutica, Universidad de Navarra, Campus Universitario, 31008, Pamplona, Spain
| | - Alexis Valentin
- UMR 152 PHARMA-DEV, Institut de Recherche pour le Développement IRD, Université de Toulouse UPS, Toulouse, France
| | - Giovanny Garavito
- Facultad de Ciencias, Departamento de Farmacia, Grupo de Investigación FaMeTra (Farmacología de la Medicina Tradicional y Popular), Universidad Nacional de Colombia, Sede Bogotá, Carrera 30 45-03, Bogotá D.C., 111321, Colombia.
| | - Eric Deharo
- UMR 152 PHARMA-DEV, Institut de Recherche pour le Développement IRD, Université de Toulouse UPS, Toulouse, France.,Institut de Recherche pour le Développement, Représentation IRD Ban Nasay, Saysettha District, P.O. Box 5992, Vientiane, Lao People's Democratic Republic
| |
Collapse
|